tiprankstipranks
Theravance Biopharma (TBPH)
NASDAQ:TBPH
US Market
TBPH
Theravance Biopharma
RESEARCH TOOLSreports

Theravance Biopharma (TBPH) Income Statement

354 Followers

Theravance Biopharma Income Statement

Last quarter (Q4 2025), Theravance Biopharma's total revenue was $45.89M, an increase of 144.70% from the same quarter last year. In Q4, Theravance Biopharma's net income was $61.02M. See Theravance Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 107.46M$ 64.38M$ 57.42M$ 51.35M$ 55.31M
Gross Profit
$ 101.95M$ 64.38M$ 16.80M$ -12.05M$ -138.35M
Operating Expenses
$ 115.19M$ 111.33M$ 72.84M$ 79.91M$ 119.44M
Depreciation and Amortization
$ 5.51M$ 3.62M$ 2.00M$ 3.04M$ 4.81M
EBITDA
$ -7.73M$ -38.45M$ -51.65M$ -76.08M$ -232.83M
Operating Income
$ -13.25M$ -46.95M$ -56.03M$ -91.96M$ -257.78M
Other Income/Expenses
$ 142.49M$ 2.33M$ 6.77M$ -858.00K$ -7.44M
Pretax Income
$ 129.25M$ -44.61M$ -49.27M$ -92.81M$ -265.22M
Net Income
$ 105.89M$ -56.42M$ -55.19M$ 872.13M$ -199.43M
Per Share Metrics
Basic EPS
$ 2.10$ -1.15$ -1.00$ -1.26$ -2.87
Diluted EPS
$ 2.06$ -1.15$ -1.00$ -1.26$ -2.87
Weighted Average Shares Outstanding
 50.32M 48.85M 55.30M 73.59M 69.46M
Weighted Average Shares Outstanding (Diluted)
 51.51M 48.85M 55.30M 73.59M 69.46M
Currency in USD

Theravance Biopharma Earnings and Revenue History